NCT05897879

Impact of Bacterial Expression and Immune Response in the Severity of Pertussis

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 210 (estimated)
• Sponsor: Institut Pasteur · Industry
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

The resurgence of pertussis is associated with an evolutionary mechanism under the pressure of current acellular vaccines, with a possible impact on vaccine effectiveness and disease expression. Little is known about the mechanisms involved in the clinical variability of pertussis, including its most severe malignant form observed in infants (mortality between 50-80%). The main challenges are: (i) the lack of knowledge about the gene expression of B. pertussis strains currently circulating during human infection, incorporating evolutionary changes and vaccine-induced selective pressure; (ii) the poor understanding of the variability in clinical expression of pertussis, and (iii) the lack of biomarkers to predict disease severity or prognosis in infants. An integrative strategy combining a clinical, microbiological, immunological and 'omic' approach from a prospective cohort of children with pertussis will be used to identify 1. 'in situ' expression profiles of B. pertussis genes and proteins incorporating recent evolutionary changes and 2. a systemic and respiratory immune signature in B. pertussis-infected children according to severity. Results should furthermore serve as a prerequisite for the identification of severity biomarkers and new vaccine antigen candidates taking into account specific immune responses in infants.

Detailed description

The study design is characterized by 4 work packages: 1. Collection of clinical data and biological samples (deep nasal swab, blood sample) from children with pertussis 2. Construction and validation of a microbial panel of 200 genes of interest (involved in virulence and/or potential vaccine antigens) for transcriptomic analysis 3. Transcriptomic study using the panel of interest of B. pertussis isolates from nasopharyngeal swabs preserved with an RNA stabilizer, using the Nanostring® technique 4. Study of the immune response during pertussis

Conditions

• Bordetella Pertussis, Whooping Cough

Interventions

Type	Name	Description
BIOLOGICAL	Nasopharyngeal swab	For hospitalized patients : Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril)) For ambulatory patients : Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated.
BIOLOGICAL	Blood samples	For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling

Timeline

• Start date: 2023-11-16
• Primary completion: 2025-11-16
• Completion: 2026-11-16
• First posted: 2023-06-09
• Last updated: 2024-05-24

Locations

14 sites across 1 country: France